Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
CytoDyn Inc CYDY
(Total Views: 505)
Posted On: 08/21/2022 3:49:09 PM
Post# of 154883
Posted By: MGK_2
Re: Emmitt #127906
Prevalence for ITP is 3.3 per 100,000 people. In the US, there are 329,500,000 people. That med the patient is on is likely Prednisone. Cortisone is a steroid with significant side effects. However, with Leronlimab, there are no side effects.

Now if Leronlimab were prescribed for it 100%, that would turn out to be 10,874 patients with an injection weekly, or every 2 or 3 or 4 weeks depending on severity of the disease and how well Leronlimab worked.

A normal platelet count is between 150,000 and 400,000. Provided it got patients platelet levels greater than 150,000, leronlimab would be considered effective.

So although it may be considered "Rare", even this rare disease could turn out to be very profitable and worth pursuing if it proves effective in early trials.













(3)
(0)









  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site